Recently, this strategy was clinically tested in patients with transthyretin amyloidosis (ATTR) using lipid nanoparticles (LNP) containing a CRISPR-Cas9 system targeting the aberrant transthyretin (TTR) in the liver. This evidence concerns the gene TTR and Familial transthyretin-related amyloidosis.